2-phenyl-N-[4-(toluene-3-sulfonyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl]-propionamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-phenyl-N-[4-(toluene-3-sulfonyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl]-propionamide
• 英文别名: N-[4-(3-methylphenyl)sulfonyl-2,3-dihydropyrido[3,2-b][1,4]oxazin-6-yl]-2-phenylpropanamide
• 化学式: C₂₃H₂₃N₃O₄S
• 分子量: 437.519
• InChiKey: CUWOGHPTEWUAIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  97
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  6-溴-2-硝基吡啶-3-醇 在 盐酸 、 tris-(dibenzylideneacetone)dipalladium(0) 、 benzophenone imine 、 铁粉 、 potassium carbonate 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 、 吡啶 、 N-甲基吡咯烷酮 、 甲醇 、 二甲基亚砜 为溶剂， 反应 42.5h， 生成 2-phenyl-N-[4-(toluene-3-sulfonyl)-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl]-propionamide
  参考文献：
  名称：

  [EN] TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
  [FR] TÉTRAHYDRO[1,8]NAPHTYRIDINE-SULFONAMIDE ET COMPOSÉS APPARENTÉS POUR UTILISATION EN TANT QU'AGONISTES DE RORGamma ET DANS LE TRAITEMENT D'UNE MALADIE

  摘要：

  公开号：

  WO2013169864A3

文献信息

• Tetrahydro[1,8]naphthyridine Sulfonamide and Related Compounds for Use as Agonists of RORy and the Treatment of Disease
  申请人：Lycera Corporation

  公开号：US20150133437A1

  公开（公告）日：2015-05-14

  The invention provides tetrahydro[1,8]naphthyridine and related compounds, methods of promoting RORy activity and/or increasing the amount of iL-17 in a subject, and therapeutic uses of the tetrahydro[1,8]naphthyridine and related compounds. In particular, the invention provides sulfonamide-tetrahydro[1,8]naphthyridine and related compounds, methods of using such compounds to promote RORy activity and/or increase the amount of iL-17 in a subject, and treat medical conditions in which activation of immune response would be beneficial such as in cancer and infections.

  该发明提供了四氢[1,8]萘啶及其相关化合物，促进RORy活性和/或增加主体中iL-17数量的方法，并且提供了四氢[1,8]萘啶及其相关化合物的治疗用途。特别地，该发明提供了磺酰胺-四氢[1,8]萘啶及其相关化合物，使用这些化合物促进RORy活性和/或增加主体中iL-17数量的方法，并治疗激活免疫反应有益的医疗状况，如癌症和感染。
• Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
  申请人：Lycera Corporation

  公开号：US09394315B2

  公开（公告）日：2016-07-19

  The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting RORγ activity, increasing the amount of IL-17 in a subject, and treating cancer, bacterial infections, and fungal infections using such tetrahydro[1,8]naphthyridine and related compounds.

  本发明提供四氢[1,8]萘啉及其相关化合物、制药组合物、促进RORγ活性的方法、增加受试者体内IL-17的数量以及使用这种四氢[1,8]萘啉及其相关化合物治疗癌症、细菌感染和真菌感染的方法。
• TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF ROR-GAMMA AND THE TREATMENT OF DISEASE
  申请人：Lycera Corporation

  公开号：EP2847198B1

  公开（公告）日：2016-12-14
• Tetrahydro[1,8]naphthyridine Sulfonamide And Related Compounds for Use as Agonists of RORy and the Treatment of Disease
  申请人：Lycera Corporation

  公开号：US20160318951A1

  公开（公告）日：2016-11-03

  The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting RORγ activity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.
• Adoptive Cellular Therapy Using an Agonist of Retinoic Acid Receptor-Related Orphan Receptor Gamma & Related Therapeutic Methods
  申请人：LYCERA CORPORATION

  公开号：US20170007686A1

  公开（公告）日：2017-01-12

  The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (RORγ) and provides adoptive cellular therapies using an agonist of RORγ, populations of lymphocyte cells that have been exposed to an agonist of RORγ, populations of dendritic cells that have been exposed to an agonist of RORγ, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of RORγ to a patient.